Basit öğe kaydını göster

dc.contributor.authorÇekdemir, D.
dc.contributor.authorGüvenç, S.
dc.contributor.authorÖzdemirkıran, F.
dc.contributor.authorEser, A.
dc.contributor.authorToptaş, T.
dc.contributor.authorÖzkocaman, V.
dc.contributor.authorKüçükkaya, R.D.
dc.date.accessioned2020-11-20T16:46:07Z
dc.date.available2020-11-20T16:46:07Z
dc.date.issued2019
dc.identifier.issn1300-7777
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2019.2018.0307
dc.identifier.urihttps://hdl.handle.net/20.500.12809/5611
dc.descriptionPubMed ID: 31327186en_US
dc.description.abstractObjective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP). Materials and Methods: A total of 285 chronic ITP patients (187 women, 65.6%; 98 men, 34.4%) followed in 55 centers were enrolled in this retrospective cohort. Response to treatment was assessed according to platelet count (/mm3) and defined as complete (platelet count of > 100,000/mm3), partial (30,000-100,000/mm3 or doubling of platelet count after treatment), or unresponsive (< 30,000/mm3). Clinical findings, descriptive features, response to treatment, and side effects were recorded. Correlations between descriptive, clinical, and hematological parameters were analyzed. Results: The median age at diagnosis was 43.9±20.6 (range: 3-95) years and the duration of follow-up was 18.0±6.4 (range: 6-28.2) months. Overall response rate was 86.7% (n=247). Complete and partial responses were observed in 182 (63.8%) and 65 (22.8%) patients, respectively. Thirty-eight patients (13.4%) did not respond to eltrombopag treatment. For patients above 60 years old (n=68), overall response rate was 89.7% (n=61), and for those above 80 years old (n=12), overall response rate was 83% (n=10). Considering thrombocyte count before treatment, eltrombopag significantly increased platelet count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time required for partial or complete response increased, response to treatment was significantly reduced. The time to reach the maximum platelet levels after treatment was quite variable (1-202 weeks). Notably, the higher the maximum platelet count after eltrombopag treatment, the more likely that side effects would occur. The most common side effects were headache (21.6%), weakness (13.7%), hepatotoxicity (11.8%), and thrombosis (5.9%). Conclusion: Results of the current study imply that eltrombopag is an effective therapeutic option even in elderly patients with chronic ITP. However, patients must be closely monitored for response and side effects during treatment. Since both response and side effects may be variable throughout the follow-up period, patients should be evaluated dynamically, especially in terms of thrombotic risk factors. ©Copyright 2019 by Turkish Society of Hematology Turkish Journal of Hematology, Published by Galenos Publishing House.en_US
dc.item-language.isoengen_US
dc.publisherTurkish Society of Hematologyen_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEltrombopagen_US
dc.subjectImmune Thrombocytopenicen_US
dc.subjectThrombocytopeniaen_US
dc.titleRefrakter kronik immün trombositopeni tedavisinde eltrombopagın etkinliğine ilişkin çok merkezli bir çalışma: Gerçek yaşam deneyimien_US
dc.item-title.alternativeA multi-center study on the efficacy of eltrombopag in management of refractory chronic immune thrombocytopenia: A real-life experience [Refrakter kronik immün trombositopeni tedavisinde eltrombopagın etkinliğine ilişkin çok merkezli bir çalışma: Gerçek yaşam deneyimi]en_US
dc.item-typearticleen_US
dc.contributor.departmenten_US
dc.contributor.departmentTempÇekdemir, D., Anadolu Medical Center, Bone Marrow Transplantation Center, Department of Hematology, Kocaeli, Turkey -- [Güvenç, S., Yeni Yüzyıl University Gaziosmanpaşa Hospital, Department of Hematology, İstanbul, Turkey -- [Özdemirkıran, F., İzmir Atatürk Training and Research Hospital, Clinic of Hematology, İzmir, Turkey -- [Eser, A., Marmara University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey -- [Toptaş, T., Marmara University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Turkey -- [Özkocaman, V., Uludağ University, Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Bursa, Turkeyen_US
dc.identifier.doi10.4274/tjh.galenos.2019.2018.0307
dc.identifier.volume36en_US
dc.identifier.issue4en_US
dc.identifier.startpage230en_US
dc.identifier.endpage237en_US
dc.relation.journalTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster